Detalhe da pesquisa
1.
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
J Cell Mol Med
; 26(24): 5976-5983, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36453136
2.
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.
Biol Blood Marrow Transplant
; 26(1): 34-43, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31605820
3.
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Haematologica
; 108(12): 3433-3437, 2023 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37259597
4.
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol
; 94(8): E209-E213, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31056762
5.
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Blood Adv
; 6(7): 2055-2068, 2022 04 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34666344
6.
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
Leuk Lymphoma
; 63(12): 2918-2922, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35811554